Financial Statements · From SEC 10-K & 10-Q XBRL Filings
Abbott Laboratories Revenue & Financial Statements
Abbott Laboratories reported revenue of $44.3B for the fiscal year ended December 31, 2025, up 5.7% year over year, with net income of $6.5B and diluted EPS of $3.72.
- Company
- Abbott Laboratories ABT · NYSE
- Latest fiscal year
- FY ended Dec 31, 2025
- Statements
- Income · Balance Sheet · Cash Flow — 5 fiscal years, 8 quarters
Income Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | 43.1B | 43.7B | 40.1B | 42.0B | 44.3B |
| Cost of revenue | 18.5B | 19.1B | 18.0B | 18.7B | 19.3B |
| Gross profit | 24.5B | 24.5B | 22.1B | 23.2B | 25.0B |
| Operating income | 8.4B | 8.4B | 6.5B | 6.8B | 8.1B |
| Pretax income | 3.3B | 3.7B | 1.2B | 947.0M | 6.7B |
| Net income | 7.0B | 6.9B | 5.7B | 13.4B | 6.5B |
| Diluted EPS | 3.94 | 3.91 | 3.26 | 7.64 | 3.72 |
| EBITDA | 9.9B | 9.6B | 7.8B | 8.2B | 9.5B |
Quarterly
| USD | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 10.0B | 10.4B | 10.6B | 11.0B | 10.4B | 11.1B | 11.4B | 11.5B |
| Cost of revenue | 4.5B | 4.6B | 4.7B | 4.9B | 4.5B | 4.9B | 5.1B | 4.9B |
| Gross profit | 5.5B | 5.8B | 5.9B | 6.0B | 5.9B | 6.3B | 6.3B | 6.5B |
| Operating income | 1.4B | 1.7B | 1.9B | 1.9B | 1.7B | 2.1B | 2.1B | 2.3B |
| Pretax income | 1.4B | 1.6B | 1.9B | 2.0B | 1.8B | 2.1B | 2.2B | 2.4B |
| Net income | 1.2B | 1.3B | 1.6B | 9.2B | 1.3B | 1.8B | 1.6B | 1.8B |
| Diluted EPS | 0.70 | 0.74 | 0.94 | 5.26 | 0.76 | 1.01 | 0.94 | 1.02 |
| EBITDA | 1.7B | — | 2.2B | 2.3B | 2.0B | 2.4B | 2.4B | 2.6B |
Balance Sheet
Fiscal year-end snapshots. Values in USD.
| USD | FY2024 | FY2024 | FY2025 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Total assets | — | 81.4B | — | 86.7B | — |
| Current assets | — | 23.7B | — | 26.0B | — |
| Cash & equivalents | — | 7.6B | — | 8.5B | — |
| Total liabilities | — | — | — | — | — |
| Current liabilities | — | 14.2B | — | 16.5B | — |
| Long-term debt | — | 12.6B | — | 9.9B | — |
| Total debt | — | 12.6B | — | 9.9B | — |
| Stockholders’ equity | — | 47.7B | — | 52.1B | — |
| Net debt | — | 5.0B | — | 1.4B | — |
Cash Flow Statement
Annual, as reported in 10-K filings. Values in USD.
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | 10.5B | 9.6B | 7.3B | 8.6B | 9.6B |
| Investing cash flow | (2.0B) | (1.7B) | (3.1B) | (2.3B) | (2.4B) |
| Financing cash flow | (5.5B) | (7.6B) | (7.1B) | (5.4B) | (6.3B) |
| Capital expenditure | 1.9B | 1.8B | 2.2B | 2.2B | 2.2B |
| Free cash flow | 8.6B | 7.8B | 5.1B | 6.4B | 7.4B |
| Dividends paid | — | — | — | — | — |
| Stock-based compensation | 640.0M | 685.0M | 644.0M | 673.0M | 664.0M |
Figures are parsed from SEC XBRL company facts and may be derived where issuers report year-to-date values (quarterly figures differenced; Q4 computed as FY minus Q3). Fiscal periods follow each company's fiscal calendar, not calendar years. Historical fact, not investment advice — verify with official SEC filings.
Every ABT filing, connected
Financials beside price, insider trades, and 8-K events — with alerts the moment something new is filed.